Home
    • Plans Blog Contact
    Icecure Medical Ltd logo

    Icecure Medical Ltd

    ICCM
    Last price US$3.11
    Market cap US$391.9m
    12M price change N/A
    Loading the 12-month Mave Thesis and 1-month news signal

    Industry and sector peers, plus broader research alternatives

    View comparison
    Abbott LaboratoriesABT Industry peer DexCom IncDXCM Industry peer Edwards Lifesciences CorpEW Industry peer Zoetis IncZTS Sector peer
    Overview Earnings Report Price History News Competitors Earnings per Share Return on Equity Net Margin Share Buyback Leverage Financial Statements Financial Ratio
    Dashboard Funda..tals Prediction Screener Map

    Icecure Medical Ltd Overview

    Industry: Medical Devices

    Sector: Healthcare

    IceCure Medical Ltd, a commercial stage medical device company, engages in the research, development, and commercialization of medical devices for cryoablation (freezing) of tumors in the human body. It offers ProSense system, a single probe system for the treatment of breast tumors; and IceSense3 system for ablation indications to urology, oncology, dermatology, gynecology, general surgery, thoracic surgery, and proctology. The company was incorporated in 2006 and is headquartered in Caesarea, Israel. IceCure Medical Ltd, a commercial stage medical device company, engages in the research, development, and commercialization of medical devices for cryoablation (freezing) of tumors in the human body. It offers ProSense system, a single probe system for the treatment of breast tumors; and IceSense3 s Read More

    Mavefund brings filings, fundamentals, valuation, price history and news for Icecure Medical Ltd into one research view. The sections below show what strengthens or weakens the research case.

    Score

    Reported Results

    What the company reported, with filing details kept small.

    Filed Aug 12, 2026

    Quarterly result summary

    Revenue was $1.8M (+45% YoY); EPS was $3.17 (reported).

    Revenue $1.8M +45% YoY
    EPS $3.17 reported

    What changed

    • Revenue +45% YoY to $1.8M; EPS reported to $3.17.

    Guidance / outlook

    We expect that our sales and marketing expenses will materially increase as we continue to enhance our market penetration efforts and recruit additional sales and marketing employees.

    Earnings release Open filing

    Source: SEC EDGAR company-filed earnings materials. Dates are shown only for verification; review the source filing before relying on extracted report details.

    Other recent earnings materials
    Earnings release PRESS RELEASE TITLED "ICECURE REPORTS ITS FINANCIAL RESULTS FOR THE FIRST HALF OF 2026 WITH 45% REVENUE GROWTH YEAR-OVER-YEAR" Aug 12, 2026 SEC filing REPORT OF FOREIGN PRIVATE ISSUER Jun 25, 2026 Earnings release PRESS RELEASE ISSUED BY ICECURE MEDICAL LTD., DATED JUNE 25, 2026, TITLED "ICECURE REGAINS COMPLIANCE WITH NASDAQ MINIMUM BID PRICE REQUIREMENT." Jun 25, 2026 Earnings release PRESS RELEASE DATED JUNE 17, 2026, TITLED "ICECURE REPORTS 70% GROWTH IN ACTIVE U.S. COMMERCIAL INSTALL BASE FOR BREAST CANCER CRYOABLATION FOLLOWING FDA CLEARANCE." Jun 18, 2026 Earnings release PRESS RELEASE DATED JUNE 17, 2026, TITLED "ICECURE ANNOUNCES PRICING OF $5.5 MILLION PRIVATE PLACEMENT PRICED AT A PREMIUM TO THE MARKET PRICE WITH A SINGLE HEALTHCARE FOCUSED INSTITUTIONAL INVESTOR." Jun 18, 2026 SEC filing REPORT OF FOREIGN PRIVATE ISSUER Jun 02, 2026 Earnings release PRESS RELEASE ISSUED BY ICECURE MEDICAL LTD., DATED JUNE 2, 2026, TITLED "ICECURE MEDICAL ANNOUNCES 1-FOR-30 REVERSE SHARE SPLIT TO SUPPORT NASDAQ COMPLIANCE." Jun 02, 2026 SEC filing REPORT OF FOREIGN PRIVATE ISSUER May 19, 2026 Earnings release PRESS RELEASE DATED MAY 19, 2026, TITLED "ICECURE'S PROSENSE REPORTS NEARLY 90% RECURRENCE-FREE RATE FOR CRYOABLATION OF KIDNEY CANCER: DATA PRESENTED AT ECIO 2026 AND FIRST-EVER BREAST CRYOABLATION MASTER CLASS OVERBOOKED" May 19, 2026 SEC filing REPORT OF FOREIGN PRIVATE ISSUER May 13, 2026 Earnings release PRESS RELEASE DATED MAY 13, 2026, TITLED "ICECURE GRANTED 180-DAY EXTENSION BY NASDAQ TO REGAIN COMPLIANCE WITH MINIMUM BID REQUIREMENT." May 13, 2026

    Prediction-grade evidence

    Recent News

    Company-relevant articles from sources that pass the Mave Signal relevance and reliability checks.

    Earnings Per Share

    Score 2.00/5
    Icecure Medical Ltd earns a low score, as its Earnings Per Share (EPS) has not shown continuous growth over the last six years. Notable counterparts in the sector with high scores includes Zoetis Inc IQVIA Holdings Inc Agilent Technologies Inc
    In Medical Devices industry , Abbott Laboratories , DexCom Inc , Edwards Lifesciences Corp are companies with high ratings.

    Return on Equity

    Score -0.24/5
    Icecure Medical Ltd exhibits a lower score in the Return on Equity (ROE) section, falling below the sector median value and indicating a comparatively weaker performance in this metric. The top companies in the same sector include Zoetis Inc IQVIA Holdings Inc Agilent Technologies Inc
    Icecure Medi... ICCM US$391.9m
    Zoetis Inc ZTS US$31.9b
    IQVIA Holdin... IQV US$34.8b
    Agilent Tech... A US$37.9b

    Net Margin

    Score 0.95/5
    Icecure Medical Ltd olds a low score as its net margin consistently trails below the sector median value and doesn't exhibit continuous growth over the last six years; notable companies in the sector with commendable scores include Zoetis Inc IQVIA Holdings Inc Agilent Technologies Inc
    Icecure Medi... ICCM US$391.9m
    Zoetis Inc ZTS US$31.9b
    IQVIA Holdin... IQV US$34.8b
    Agilent Tech... A US$37.9b

    Share Buyback

    In Medical Devices industry , Abbott Laboratories , DexCom Inc , Edwards Lifesciences Corp are companies with high ratings.

    Leverage

    Score 2.50/5
    Icecure Medical Ltd registers a lower score in the category as a result of its elevated leverage ratio over the past six years compared to the sector median value. Conversely, other companies in the same sector, including Zoetis Inc IQVIA Holdings Inc Agilent Technologies Inc have achieved high scores.
    Icecure Medi... ICCM US$391.9m
    Zoetis Inc ZTS US$31.9b
    IQVIA Holdin... IQV US$34.8b
    Agilent Tech... A US$37.9b

    Financial Statements

    Company-reported SEC EDGAR facts organized into the three core statements.

    Reported currency
    Verified SEC statements load when this section enters view.

    Source: SEC EDGAR companyfacts. Values are standardized company filings for research support, not personalized financial advice.

    Financial Ratio

    Yearly Quarterly

    Financial
    Profitability
    Growth
    Cash Flow
    Financial Health
    Efficiency Ratios

    Icecure Medical Ltd logo

    Icecure Medical Ltd

    US$3.11

    US$391.9m

    0.07%

    N/A